0.00Open1.81Pre Close0 Volume210 Open Interest26.00Strike Price0.00Turnover47.61%IV0.18%PremiumNov 8, 2024Expiry Date1.76Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.9300Delta0.1066Gamma15.34Leverage Ratio-0.0258Theta0.0022Rho14.26Eff Leverage0.0035Vega
Pfizer Stock Discussion
According to the Securities Times APP, on November 5, the official website of the National Medical Products Administration (NMPA) showed that Pfizer's talazoparib tosylate capsules (talazoparib) have been approved for marketing. Talazoparib was originally developed by BioMarin, acquired by Medivation from BioMarin in 2015, and Pfizer acquired Medivation for $14 billion in 2016, thus talazoparib belongs to Pfizer since then.
10M in volume with over 5B free float.. This will always be a shorts paradise.. Too many outstanding shares for such a cheap stock!🤢🤮
wow... talk about a sh*show with this stock!
🤢🤮
in terms of risk vs earnings
$15 - $20 range should be fair value range
margin of safety $10 - $15
XLV is downtrending
No comment yet